|1.||Gonyeau, Michael J: 1 article (01/2014)|
|2.||Kah, Janine: 1 article (09/2012)|
|3.||Tiegs, Gisa: 1 article (09/2012)|
|4.||Montalbano, Roberta: 1 article (09/2012)|
|5.||Volz, Tassilo: 1 article (09/2012)|
|6.||Sirma, Hüseyin: 1 article (09/2012)|
|7.||Wüstenberg, Andrea: 1 article (09/2012)|
|8.||Dandri, Maura: 1 article (09/2012)|
|9.||Sass, Gabriele: 1 article (09/2012)|
|10.||Ocker, Matthias: 1 article (09/2012)|
01/01/2014 - "Such studies should consider three main end products of the mevalonate pathway (cholesterol, geranyl pyrophosphate, and farnesyl pyrophosphate) from a mechanistic perspective, as well as the potential for cancer cell mediation with statin use, in addition to pertinent clinical end points including cancer incidence and mortality. "
09/01/2012 - "The anti-tumor effect of statins did not depend on a lack of cholesterol production, but was restored by supplementation of mevalonate or geranyl-geranyl pyrophosphate, prerequisites for prenylation of small G proteins. "
01/01/2008 - "Indeed the cholesterol synthesis pathway plays a pivotal role in dislypidemia and, ultimately, in cancer through intermediates such as mevalonate, farnesyl pyrophosphate and geranyl geranyl pyrophosphate, but no dynamic model of this pathway has been proposed until now. "
|2.||Wounds and Injuries (Trauma)
|1.||Mevalonic Acid (Mevalonate)
|3.||farnesyl pyrophosphate (farnesyl diphosphate)
|4.||Monomeric GTP-Binding Proteins
|5.||pinene cyclase I (limonene synthase)